



For publication in the News section at home page

The Francis Crick Institute Renews the Research License Agreement with ExpreS²ion Biotechnologies

Horsholm, Denmark, June 26, 2017 – Today, ExpreS²ion Biotechnologies ApS (“ExpreS²ion”), a fully owned subsidiary of ExpreS²ion Biotech Holding AB, announces that the Francis Crick Institute, London, United Kingdom, has agreed to amend the Research License Agreement about ExpreS²ion’s proprietary ExpreS² expression system for another year.

The Research License Agreement

In July 2015 ExpreS²ion and the Francis Crick Institute entered into a one-year Research License Agreement whereby The Francis Crick Institute was granted access to research based on ExpreS²ion’s proprietary ExpreS² system. The Research License Agreement is now amended to be effective for a third full year term. ExpreS²ion and The Francis Crick Institute are not disclosing any terms for extending the Research License Agreement.

About the Francis Crick Institute

The Francis Crick Institute is a biomedical discovery institute which brings together 1500 scientists and support staff working collaboratively across disciplines, making it the biggest biomedical research facility under a single roof in Europe working in areas as cancer, heart disease, stroke, infections, and neurodegenerative diseases. The Francis Crick Institute was founded by six of the UK’s most successful scientific and academic organisations - the Medical Research Council (MRC), Cancer Research UK (CRUK), the Wellcome Trust, UCL (University College London), Imperial College London and King’s College London. For more information, please visit: www.crick.ac.uk

For further information, please contact:

ExpreS²ion Biotechnologies,
Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com

About ExpreS²ion

ExpreS²ion Biotechnologies ApS, is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique platform technology, ExpreS², enabling cost effective development and robust production of complex proteins for new vaccines and diagnostics for e.g. Malaria and Zika. Since founded in 2010, the company has used its patented ExpreS² platform to produce more than 200 proteins in collaborations with research institutions and biopharmaceutical companies, with a superior efficiency and success rate.